Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CIK_D232 |
| Trade Name | |
| Synonyms | CIK D232|CIK-D232 |
| Drug Descriptions |
CIK_D232 comprises cytokine-induced killer cells generated through a blinatumomab-based protocol that includes stimulation of peripheral blood mononuclear cells with IFN-gamma, IL2, and anti-CD3 monoclonal antibodies, which potentially induces antitumor activity (PMID: 38721751). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| CIK_D232 | CIK_D232 | 0 | 0 |
| CIK_D232 + Lenalidomide + Tafasitamab-cxix | CIK_D232 Lenalidomide Tafasitamab-cxix | 0 | 1 |